CHMO
Chimeric Therapeutics Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
2
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Chimeric Therapeutics Limited - Option Expiring 31-Mar-2024
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.00
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CHMO
2
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in CHMO
N/A
CHMO investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
50%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in CHMO also invest in...
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
📊 Share price
$29.97 AUD
NULL GLOBAL
NULL SMART BETA
NULL ETHICAL
NULL THEMATIC
FAIR.AX was created on 2017-11-27 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes Australian companies that have passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
📊 Share price
$18.55 AUD
NULL AUSTRALIA
NULL NEW ZEALAND
NULL ETHICAL
NULL THEMATIC
NULL SUSTAINABLE
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
📊 Share price
$43.11 AUD
NULL US
NULL EX AUSTRALIA
NULL BETA
VAE.AX was created on 2015-12-09 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard FTSE Asia ex Japan Shares Index ETF seeks to track the return of the FTSE Asia Pacific ex Japan, Australia and New Zealand Index (with net dividends reinvested) in Australian dollars, before taking into account fees, expenses and tax.
📊 Share price
$68.93 AUD
NULL OTHER
NULL EX JAPAN
NULL ASIA
NULL EX AUSTRALIA
NULL BETA
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its HER-Vaxx is a B-cell immuno-therapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. PD1-Vaxx is a B-cell immuno-therapy, which aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer. Its clinical trial candidates include VAXINIA, CHECKvacc, B-Vaxx and others. Its platform technologies seek to harness the body’s immune system against tumors.
📊 Share price
$0.11 AUD
NULL HEALTH
Want more shares? Try these...
Chalice Mining Ltd. engages in the development of mineral projects. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-03-24. The Company’s projects include Julimar Nickel-Copper-PGE and Hawkstone Nickel-Copper-Cobalt. The Julimar Nickel-Copper-PGE Project is located approximately 70 kilometers (km) north-east of Perth. The Project is favorably located, with road, rail, port and high-voltage power infrastructure nearby, plus access to a significant drive-in/drive-out mining workforce in Perth surrounds. The Hawkstone Nickel-Copper-Cobalt Project covers an area of approximately 1,800 square kilometers (km2) in the west Kimberley region of Western Australia. The Project covers various areas of Ruins and Hart Dolerite, which are both considered highly prospective for magmatic nickel sulfides, as well as other related metals (Cu, Co, PGEs, Au, Sn, W).
📊 Share price
$7.11 AUD
Charger Metals NL operates as a lithium and other base metals mining company. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2021-07-09. The principal activity of the Company is to acquire interests in mineral exploration and evaluation tenements, conducting exploration work on those interests as well as seeking out further exploration, acquisition and joint venture opportunities. Its projects include Bynoe Lithium Project, Lake Johnston Lithium Project and Coates Ni Cu Co Platinum Group Elements (PGE) Project. The Bynoe Lithium Project occurs within the Pine Creek orogen, which includes the Bynoe Pegmatite Field. The Project is located approximately 38 kilometers (km) southwest of Darwin in the Northern Territory. The Lake Johnston Lithium Project covers parts of the Archaean-aged Lake Johnston Greenstone Belt. The project is located approximately 450 km east of Perth. The Coates Ni Cu Co Platinum Group Elements (PGE) Project is located about 28 km southeast of the Julimar Project.
📊 Share price
$0.56 AUD
Camplify Holdings Ltd. operates in the RV rental market. The firm has built a platform that delivers transparent experiences for consumers and RV hirers to connect with RV owners and small and medium-sized enterprises (SMEs) with a fleet of RVs. Its businesses include Camplify and PaulCamper. Its segments include Hire, Membership and Other. The firm provides a range of caravans, motorhomes, camper trailers and campervans for hire via the respective platforms. The firm has operations in Australia, New Zealand, Spain, United Kingdom, Germany, Austria and Netherlands. Its subsidiaries include Camplify Co (Australia) Pty Ltd, Camplify Co (NZ) Limited, Camplify Co (UK) Limited, Plataforma Camplify Espana, S.L and PaulCamper GmbH.
📊 Share price
$1.95 AUD
Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase I clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The firm is also focused on the development of four NK and CAR NK assets with plans for Phase I clinical trials in solid tumors and blood cancers.
📊 Share price